Life Sciences Personalized Nutrition Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Personalized Nutrition Platforms
1.1 - About Life Sciences Personalized Nutrition Platforms sector
Companies in the Life Sciences Personalized Nutrition Platforms category build data-driven tools and services that translate genomics, microbiome, biomarker, and lifestyle inputs into individualized diet and supplement plans. These vendors combine testing pipelines, analytics, recommendation engines, and longitudinal monitoring to support evidence-based nutrition programs. Their solutions enable scalable personalization, secure health data management, and measurable outcomes for both clinical providers and consumer wellness brands.
Offerings typically span end-to-end sample collection workflows and laboratory integrations for DNA, blood, and stool assays, which feed AI-driven recommendation engines that generate individualized dietary protocols. To operationalize programs, vendors layer meal planning and personalized supplement formulation with wearable and EHR data ingestion, mobile coaching and telehealth tools, outcomes analytics and reporting, plus HIPAA/GDPR compliance, consent management, and subscription fulfillment.
Primary customers include consumer wellness platforms, nutraceutical brands, and lifestyle medicine or telehealth clinics seeking to deliver precision nutrition. These solutions drive higher member engagement and retention, differentiated product lines with data-backed claims, improved clinical markers such as glycemic control or lipid profiles, and operational efficiency through integrated testing, coaching, and fulfillment.
2. Buyers in the Life Sciences Personalized Nutrition Platforms sector
2.1 Top strategic acquirers of Life Sciences Personalized Nutrition Platforms companies
Viome
HQ: United States
Website
- Description: Provider of direct-to-consumer at-home RNA testing that analyzes microbial and human gene expression to map an individual’s internal biochemistry and microbiome, delivering personalized, adaptive nutrition and health recommendations through technology licensed from Los Alamos National Laboratory.
- Key Products:
- Gut Intelligence™ Test: At-home stool test uses RNA sequencing to analyze microbial gene expression, delivers 20+ gut health scores and food recommendations within 2-3 weeks via the Viome app, identifying inflammation and metabolic issues
- VRx My·Biotics™ Gut Formula: Personalized monthly stick pack blending clinically studied probiotic strains and targeted prebiotic fibers matched to the customer’s microbiome to restore balance, improve digestion and support gut resilience
- Precision Supplements™: Data-driven capsules custom-mixed for each user with up to 50 vitamins, minerals, herbs, enzymes and amino acids at clinically informed dosages to address specific gut and systemic health needs
- Gut Health Solutions Bundle: Integrated program combining the Gut Intelligence Test, optional Precision Supplements and VRx My·Biotics Formula, supported by AI-generated food guidance, to reduce gas, bloating, and support nutrient absorption and gut-brain health.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Personalized Nutrition Platforms sector
M&A buyer group 1: Food as Medicine
21 companies
View group →
Description: Companies in the Life Sciences Food-as-Medicine Platforms category develop clinical-grade nutrition solutions and delivery programs that integrate food into care pathways. They combine medical foods, medically tailored meals, and digital tools to prescribe, deliver, and monitor nutrition interventions for specific conditions. By linking evidence-based diets to outcomes data and reimbursement models, these vendors help payers and providers operationalize food as therapy at scale.
Zinzino
HQ: Sweden
- Type: N/A
- Employees: ●●●●●
- Description: Provider of test-based personalized nutrition, preventative health and wellness solutions. Zinzino offers omega, immune, restore and gut health supplements, home blood-spot tests for fatty acids, vitamin D and blood-sugar profiling, plus biotech skincare and weight-management products. Scientific analysis by in-house experts enables tailored recommendations; products are sold via global direct sales in 47 markets.
- Key Products:
- BalanceTest: Self-administered dried blood spot test measuring Omega-6:3 ratio and dietary markers, delivering detailed readings used to personalize subsequent nutrition and wellness recommendations
- Zinzino Health Protocol: Step-by-step, individualized nutrition program translating BalanceTest results into tailored supplement regimen, eliminating guesswork and guiding users toward healthier lifestyle changes
- BalanceOil products: Scientifically formulated omega-3 supplements selected according to Health Protocol to gently balance, restore and support the body’s essential fatty acid profile from within
- Test-based nutritional & skincare range: Scientifically proven, test-based nutritional and skincare products developed with pharmaco-nutrition science to meet individual needs, distributed through the company’s global direct sales network.
🔒
🔒
🔒
View all 21 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Personalized Nutrition Platforms sector
3.1 - Buyout funds in the Life Sciences Personalized Nutrition Platforms sector
2.2 - Strategic buyer groups for Life Sciences Personalized Nutrition Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Personalized Nutrition Platforms companies
4.2 - Public trading comparable groups for Life Sciences Personalized Nutrition Platforms sector
Valuation benchmark group 1: Genomics Tools and Precision Diagnostics Companies
5 companies
View group →
Description: Companies in this public trading comparables group develop and commercialize genomics tools and precision oncology diagnostics. Business models span CLIA/FDA-approved liquid biopsy assays, comprehensive genomic profiling, synthetic DNA manufacturing, and outsourced sequencing and biobanking services. They are comparable as valuation benchmarks given shared exposure to NGS workflows, recurring consumables and services revenue, payer/provider adoption cycles, and biopharma research demand.
Ford
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of a range of trucks, commercial cars and vans, sport utility vehicles, and luxury vehicles worldwide; offers retail installment sale contracts and direct financing leases for new vehicles; sells vehicles, service parts, and accessories through distributors and dealers; provides wholesale loans to dealers for vehicle inventory purchase and dealership operations.
- Key Products:
- Trucks: Range of Ford trucks with varied functionalities for different use cases
- Commercial Vehicles: Vans and commercial cars suitable for business applications
- Luxury Vehicles: Premium Lincoln-branded vehicles with advanced features and luxury
- Retail Financing: Retail installment sale contracts and direct financing leases for vehicle purchases
- Fleet Solutions: Wholesale loans to dealers for vehicle inventory and dealership operations.
🔒
🔒
🔒
View all 5 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →